Other Information.
−Removed: the three month period ended September 30, 2024, none of our executive officers or directors (as defined in Section 16 of the Securities
−Removed: Exchange Act of 1934, as amended), adopted , terminated , or modified a “Rule 10-b5-1 trading arrangement” or a “non-Rule
−Removed: 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
+Added: During the fiscal quarter ended March 31, 2025, none of the Company’s directors or officers (as defined in
+Added: Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company
+Added: securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
−Removed: Form of Senior Secured Promissory Note (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).
−Removed: Security Agreement, dated August 6, 2024, between Nirland Limited and Conduit Pharmaceuticals Inc.
−Removed: (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 7, 2024, and incorporated herein by reference).
−Removed: License Agreement, dated August 7, 2024, between AstraZeneca AB (PUBL) and Conduit Pharmaceuticals Inc.
−Removed: (filed as Exhibit 10.31 to the Registrant’s Pre-Effective Amendment No.
−Removed: 1 to Registration Statement on Form S-1 filed on September 13, 2024, and incorporated herein by reference).
−Removed: Stock Issuance Agreement, dated August 7, 2024, between AstraZeneca AB (PUBL) and Conduit Pharmaceuticals Inc.
−Removed: (filed as Exhibit 10.32 to the Registrant’s Pre-Effective Amendment No.
−Removed: 1 to Registration Statement on Form S-1 filed on September 13, 2024, and incorporated herein by reference).
Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
22 unchanged sentences
PHARMACEUTICALS INC
−Removed: David Tapolczay
−Removed: David Tapolczay
Executive Officer
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.